explore -WSS

explore

author：comprehensive 2025-09-29 22:51:41 - browse：29

Cambridge: AbbVie — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： John Green on his newest strategy for fighting tuberculosis

hotspot

WSS

Overprescribed: High cost isn't America's only drug problem

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

John Green on his newest strategy for fighting tuberculosis

Overprescribed: High cost isn't America's only drug problem

Trial using CRISPR to edit HIV out of cells disappoints

Trial using CRISPR to edit HIV out of cells disappoints

leisure time

explore

entertainment

The high cost of giving birth even with insurance

Republican states more likely to report Covid vaccine side effects

Anesthesiologist group: stop taking Ozempic before surgery

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Boston's new lab space is opening empty

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Covid silver lining: Unprecedented look at human immune system

Duchenne breakthrough therapy leaves behind pioneering families

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

Insurer loopholes limit power of law against surprise medical bills

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Study: Black kids more likely to die after surgery than white kids

HHS secretary Becerra pressed on Change HealthCare cyberattack

Ebola: Gilead Sciences antiviral shows promise as new treatment

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

knowledge

explore

hotspot

explore